Summary
Pfizer Inc. (PFE) announced its first-quarter 2023 financial results via a press release filed on May 2, 2023. This 8-K filing primarily serves to furnish the press release detailing these results. Investors should note that the information contained within this press release, while crucial for understanding the company's recent performance, is not considered "filed" under Section 18 of the Exchange Act and thus does not carry the same legal implications as a fully filed report. The core of this filing is the press release itself, which provides the operational and financial data for the first quarter of 2023. While the 8-K itself doesn't delve into the specifics of the results, it directs investors to the furnished press release (Exhibit 99) for detailed information regarding revenue, earnings, and other key financial metrics. Investors seeking to understand Pfizer's performance should refer to this press release for comprehensive insights into the company's financial condition and operational results during the period.
Key Highlights
- 1Pfizer Inc. filed an 8-K on May 2, 2023, to report its first-quarter 2023 financial results.
- 2The filing includes a press release (Exhibit 99) containing the detailed financial results.
- 3The information furnished in this 8-K is not considered 'filed' for the purposes of Section 18 of the Exchange Act.
- 4Investors should consult Exhibit 99 (the press release) for specific details on Q1 2023 performance.
- 5The 8-K serves as a notification mechanism for the release of Q1 2023 financial performance data.